Litcius/Paper detail

Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands

Ed Slot, Boris M. Hogema, Chantal Reusken, Johan Reimerink, Michel Molier, Jan H. M. Karregat, Johan IJlst, V.M.J. Novotný, René A. W. van Lier, Hans L. Zaaijer

2020Nature Communications99 citationsDOIOpen Access PDF

Abstract

The world is combating an ongoing COVID-19 pandemic with health-care systems, society and economies impacted in an unprecedented way. It is unclear how many people have contracted the causative coronavirus (SARS-CoV-2) unknowingly and are asymptomatic. Therefore, reported COVID-19 cases do not reflect the true scale of outbreak. Here we present the prevalence and distribution of antibodies to SARS-CoV-2 in a healthy adult population of the Netherlands, which is a highly affected country, using a high-performance immunoassay. Our results indicate that one month into the outbreak (i) the seroprevalence in the Netherlands was 2.7% with substantial regional variation, (ii) the hardest-hit areas showed a seroprevalence of up to 9.5%, (iii) the seroprevalence was sex-independent throughout age groups (18-72 years), and (iv) antibodies were significantly more often present in younger people (18-30 years). Our study provides vital information on the extent of exposure to SARS-CoV-2 in a country where social distancing is in place.

Topics & Concepts

SeroprevalenceOutbreakPandemicAsymptomaticCoronavirus disease 2019 (COVID-19)Social distanceMedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)PopulationDemographyVirologySerologyEnvironmental healthAntibodyImmunologyDiseaseInternal medicineInfectious disease (medical specialty)SociologySARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesCOVID-19 epidemiological studies